• Melissa Unusual MBA, from Closed Loop Drugs, joins as Chief Monetary Officer

• Jérôme Galbrun PhD, joins as Chief Income Officer, ex-Philips International Chief

• The corporate has greater than doubled its general assets following final December’s £16M ($21.2M) financing spherical, with extra hiring deliberate by way of the remainder of the 12 months

OXFORD, United Kingdom, July 19, 2022 /PRNewswire/ — Brainomix, the AI-powered medtech options firm, at the moment declares that it has appointed Melissa Unusual as Chief Monetary Officer (CFO) and Jérôme Galbrun as Chief Income Officer (CRO). The growth within the management staff displays the Firm’s development and maturity since closing its £16M ($21.2M) sequence B financing in December 2021. The staff has greater than doubled for the reason that begin of the 12 months, with extra hiring deliberate for the rest of 2022.

Melissa will lead finance, HR and operations, bringing intensive expertise to assist information the Firm’s future path. Melissa has spent 14 years working in life sciences, serving to firms resembling Summit Therapeutics and Kuano develop from early-stage discovery by way of to business launch preparations. Melissa joins from Closed Loop Drugs the place she led on finance and technique as CFO, together with closure of a £13m Sequence A financing. With expertise in company and business transactions, in addition to wider organizational growth and operational capabilities, Melissa has been actively concerned in elevating over £100M by way of UK and US non-public and public financings and helped safe ~£67M in non-dilutive funding. Melissa holds an LLB in Regulation from Oxford Brookes College and a Postgraduate Diploma in Authorized Apply from Guildford’s College of Regulation, an Govt MBA from College of Oxford, and is a chartered licensed accountant.

Jérôme will lead world gross sales, advertising and marketing and enterprise growth actions at Brainomix. He brings intensive enterprise expertise, notably from the medical system and medical imaging business. Earlier than becoming a member of Brainomix, Jérôme was Senior Director at Philips the place he held positions together with Lead International Gross sales and Enterprise Improvement for the EMR (Digital Medical Data) and Care Administration Enterprise Unit, specializing in tele-health options; and International Head of Advertising for the KLAS-awarded Superior Visualization resolution, specializing in cardiology, oncology and neurology. Previous to Philips, Jérôme was the pinnacle of International Enterprise Improvement at Agfa HealthCare and has held numerous different administration positions in giant firms, together with Hewlett-Packard and GE Healthcare. He holds a PhD in Medical Expertise Innovation Processes from the Tokyo Institute of Expertise, and a Grasp’s in Administration from the Graduate Enterprise Faculty of Lyons.

Together with Melissa and Jérôme, Brainomix has practically doubled its general staff within the final six months, including new staff members throughout important features of software program engineers, medical specialists and program managers, to assist drive the Firm’s growth into new markets and new therapeutic indications resembling lung fibrosis and most cancers. Additional appointments are deliberate by the tip of the 12 months, extending the corporate’s business and advertising and marketing operations.

Dr Michalis Papadakis, Brainomix’s Chief Govt Officer & Co-Founder, commented: “Our latest £16M financing displays our sturdy observe report and gives the assets to maximise our potential within the supply of modern AI options for sufferers worldwide. We are actually at an inflection level on a really thrilling growth pathway. I welcome Melissa and Jérôme to the management staff and look ahead to working with them as we drive ahead our healthcare innovation, best-in-class technological growth and growth into new illness indications and geographical markets.

Melissa Unusual, newly appointed CFO at Brainomix, mentioned: “I’m excited to be becoming a member of Brainomix at this important stage in its development because it scales its enterprise. The world-class staff has developed really modern know-how and its e-Stroke platform is already the market chief in Europe, in addition to being put in in tons of of hospitals throughout the US, South America and Asia. I look ahead to working with Michalis and the Brainomix staff as we increase the enterprise for additional affected person profit and worth creation.”

Jérôme Galbrun, newly appointed CRO at Brainomix, mentioned: “Brainomix has world-leading strengths in healthcare and AI-enabled medtech, and a staff that’s dedicated to positively impacting affected person therapy and outcomes world wide. I look ahead to additional advancing the market adoption of its e-Stroke platform and to commercialising different indications resembling lung fibrosis and most cancers, which have related unmet wants and are amenable to our strategy.”

The latest financing was co-led by present buyers Boehringer Ingelheim Enterprise Fund and Parkwalk Advisors, together with new investor, Tencent Holdings, and included participation from Oxford College Innovation Fund.

This funding will construct on the confirmed success of the Firm’s tech platform in stroke and allow value-generating pharmaceutical partnerships to enhance medical trial success, foster broader adoption of present therapies within the new indications, and enhance affected person outcomes. The funds may also allow the Firm to drive into new therapeutic areas past stroke by growing novel imaging biomarkers for higher therapy of lung fibrosis and most cancers.

About Brainomix

Brainomix is an Oxford-based firm specializing within the creation of AI-enabled software program options to allow precision drugs for higher therapy selections in stroke and sure lung situations. Since launching as a spin-out from the College of Oxford in 2010, it has developed award-winning, AI-powered imaging biomarkers and software program options, aiding physicians the world over to make higher life-saving selections. Its e-Stroke platform gives clinicians with probably the most complete stroke imaging resolution, driving sooner therapy instances and enhancing useful independence for sufferers. To be taught extra about Brainomix and its know-how go to www.brainomix.com, and observe on Twitter, LinkedIn and Fb.

At Brainomix

Jeff Wyrtzen, Chief Advertising & Enterprise Improvement Officer
jwyrtzen@brainomix.com
+44 (0)7927 164210
+44 (0)1865 582730

Media enquiries

Sue Charles, Charles Consultants
Sue@charles-consultants.com
+44 (0)7968 726585